"Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.

Effective therapeutics against triple negative breast cancer (TNBC), which has no standard-of-care therapy, needs to be developed urgently. Here we demonstrated a strategy of integrating indocyanine green (ICG), paclitaxel (PTX), and survivin siRNA into one thermosensitive poly(2-(2-methoxyethoxy)ethyl methacrylate-co-oligo(ethylene glycol) methacrylate)-co-2-(dimethylamino)ethyl methacrylate-b-poly(D,L-lactide-co-glycolide) (P (MEO2MA-co-OEGMA-co-DMAEMA)-b-PLGA) nanoparticle (NP-IPS) for triple-punch strategy against TNBC. The NP-IPS significantly enhanced the stability of ICG. Controlled release of the PTX in tumor regions was triggered by the hyperthermia produced by laser irradiated ICG. The NP-IPS exhibited remarkable antitumor efficacy (almost complete ablation of the tumor xenografts) due to the combinational effects of chemotherapy, photothermal therapy, and gene therapy with low drug dose (ICG, 0.32 μmol/kg; PTX, 0.54 μmol/kg; siRNA, 1.5 mg/kg) and minimal side effects. Taken together, our current study demonstrates a nanoplatform for triple-therapy, which reveals a promising strategy for TNBC treatment.

[1]  R. Zhao,et al.  Engineering the Assemblies of Biomaterial Nanocarriers for Delivery of Multiple Theranostic Agents with Enhanced Antitumor Efficacy , 2013, Advanced materials.

[2]  T. Okano,et al.  Molecular design of biodegradable polymeric micelles for temperature-responsive drug release. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[3]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[5]  L. Carey,et al.  Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.

[6]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[7]  Wang Sheng,et al.  Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. , 2014, Biomaterials.

[8]  Josephine,et al.  Binding properties of indocyanine green in human blood. , 1998, Investigative ophthalmology & visual science.

[9]  Zhuang Liu,et al.  PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. , 2008, Journal of the American Chemical Society.

[10]  龚萍,et al.  Single-Step Assembly of DOX/ICG Loaded Lipid Polymer Nanoparticles for Highly Effective Chemo-photothermal Combination Therapy , 2013 .

[11]  Tianjiao Ji,et al.  Localized electric field of plasmonic nanoplatform enhanced photodynamic tumor therapy. , 2014, ACS nano.

[12]  Farin Kamangar,et al.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Paula T. Hammond,et al.  A Convergent Synthetic Platform for Single-Nanoparticle Combination Cancer Therapy: Ratiometric Loading and Controlled Release of Cisplatin, Doxorubicin, and Camptothecin , 2014, Journal of the American Chemical Society.

[14]  Martin C Garnett,et al.  The effect of poly(ethylene glycol) molecular architecture on cellular interaction and uptake of DNA complexes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Paul C. Wang,et al.  Amphiphilic and biodegradable methoxy polyethylene glycol-block-(polycaprolactone-graft-poly(2-(dimethylamino)ethyl methacrylate)) as an effective gene carrier. , 2011, Biomaterials.

[16]  T. Ji,et al.  Multiple layer-by-layer lipid-polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models , 2016 .

[17]  Jean-François Lutz,et al.  Point by point comparison of two thermosensitive polymers exhibiting a similar LCST: is the age of poly(NIPAM) over? , 2006, Journal of the American Chemical Society.

[18]  Dong Chen,et al.  Multifunctional gold nanoshells on silica nanorattles: a platform for the combination of photothermal therapy and chemotherapy with low systemic toxicity. , 2011, Angewandte Chemie.

[19]  S. Mitragotri,et al.  Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. , 2013, ACS nano.

[20]  Jin-Oh You,et al.  A drug-delivery vehicle combining the targeting and thermal ablation of HER2+ breast-cancer cells with triggered drug release. , 2013, Angewandte Chemie.

[21]  N. Zaffaroni,et al.  Survivin as a target for new anticancer interventions , 2005, Journal of cellular and molecular medicine.

[22]  Francesco M Veronese,et al.  PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.

[23]  Peng Zhang,et al.  Inhibition of lymphatic metastases by a survivin dominant-negative mutant. , 2013, Oncology research.

[24]  John A Wagner,et al.  Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop , 2012, Clinical Cancer Research.

[25]  Chunying Chen,et al.  Selective inhibition of breast cancer stem cells by gold nanorods mediated plasmonic hyperthermia. , 2014, Biomaterials.

[26]  Leone Spiccia,et al.  Nanomaterials: Applications in Cancer Imaging and Therapy , 2011, Advanced materials.

[27]  Guangjun Nie,et al.  Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. , 2011, Biomaterials.

[28]  Paula T Hammond,et al.  Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. , 2013, ACS nano.

[29]  Kort Travis,et al.  Biodegradable near-infrared plasmonic nanoclusters for biomedical applications , 2010, BiOS.

[30]  Vishal Saxena,et al.  Degradation kinetics of indocyanine green in aqueous solution. , 2003, Journal of pharmaceutical sciences.

[31]  Yi Yan Yang,et al.  Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions. , 2005, Biomaterials.

[32]  Jianlin Shi,et al.  MSN Anti‐Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition , 2014, Advanced materials.

[33]  Robert J. Griffin,et al.  Indocyanine green enhanced near‐infrared laser treatment of murine mammary carcinoma , 2012, International journal of cancer.